Olmutinib

DRUG2 trials

Sponsors

Konkuk University Medical Center, Hanmi Pharmaceutical Company Limited

Conditions

Non Small Cell Lung Cancer

Phase 1

Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI

TerminatedNCT04510415

Hanmi Pharmaceutical Company LimitedNon Small Cell Lung Cancer

Start: 2018-03-29End: 2018-12-11Updated: 2020-08-12

Phase 2

Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA

CompletedNCT03228277

Konkuk University Medical CenterNon Small Cell Lung Cancer

Start: 2017-07-17End: 2019-07-31Updated: 2019-08-28